-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
-
This randomized, double-blind, placebo-controlled trial demonstrates that administration of erythropoietin once a week for three weeks does not reduce the incidence of red blood cell transfusion in a mixed population of critically ill patients but is associated with an increased incidence of thrombotic events and a possible decrease in mortality in trauma patients.
-
Weight gain has long been used as a marker of fluid retention in heart failure patients. It is a cheap, simple test that can be performed daily in patients' homes.
-
Two hundred eighty-eight patients hospitalized with severe community-acquired pneumonia (CAP) were followed for 28 days in a prospective multicenter study.
-
-
Early identification, coupled with appropriate control measures, reduces the rate of C. difficile infection and the frequency of adverse events.
-
In this survey of US hospitals, more than half did not have an identifiable ICU director. Loss of autonomy and income for admitting primary physicians were perceived as important barriers to implementation of the Leapfrog Group's ICU physician staffing guidelines.
-
Performance-enhancement supplements, also called ergogenic aids, remain popular among athletes. Up to 3 million people in the United States are believed to use anabolic-androgenic steroids (AAS). However, the profile of those using such drugs is broadening.
